Endpoints News
Apnimed set to exit sleep disorder joint venture with Shionogi for $100M upfront
Shionogi is doubling down on its sleep disorder pipeline by buying out Apnimed’s half of their joint venture in the niche field.
The Japanese pharma will pay $100 million upfront to buy the 50% equity …